Compare Novartis with FDC LTD. - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs FDC LTD. - Comparison Results

NOVARTIS     Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS FDC LTD. NOVARTIS/
FDC LTD.
 
P/E (TTM) x 494.2 17.2 2,879.6% View Chart
P/BV x 28.7 2.3 1,234.0% View Chart
Dividend Yield % 1.6 0.0 -  

Financials

 NOVARTIS   FDC LTD.
EQUITY SHARE DATA
    NOVARTIS
Mar-18
FDC LTD.
Mar-18
NOVARTIS/
FDC LTD.
5-Yr Chart
Click to enlarge
High Rs758319 237.6%   
Low Rs579164 353.0%   
Sales per share (Unadj.) Rs228.461.6 370.5%  
Earnings per share (Unadj.) Rs31.79.9 319.0%  
Cash flow per share (Unadj.) Rs32.812.0 273.8%  
Dividends per share (Unadj.) Rs10.000-  
Dividend yield (eoy) %1.50-  
Book value per share (Unadj.) Rs297.173.2 406.1%  
Shares outstanding (eoy) m24.69174.40 14.2%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x2.93.9 74.7%   
Avg P/E ratio x21.124.3 86.8%  
P/CF ratio (eoy) x20.420.2 101.1%  
Price / Book Value ratio x2.23.3 68.2%  
Dividend payout %31.50-   
Avg Mkt Cap Rs m16,50542,118 39.2%   
No. of employees `0000.75.5 12.1%   
Total wages/salary Rs m1,4452,167 66.7%   
Avg. sales/employee Rs Th8,441.31,943.7 434.3%   
Avg. wages/employee Rs Th2,163.6391.7 552.3%   
Avg. net profit/employee Rs Th1,173.1313.7 373.9%   
INCOME DATA
Net Sales Rs m5,63910,751 52.5%  
Other income Rs m1,718510 337.2%   
Total revenues Rs m7,35711,260 65.3%   
Gross profit Rs m-632,267 -2.8%  
Depreciation Rs m25351 7.2%   
Interest Rs m5514 395.0%   
Profit before tax Rs m1,5752,411 65.3%   
Minority Interest Rs m0-5 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m792671 117.9%   
Profit after tax Rs m7841,735 45.2%  
Gross profit margin %-1.121.1 -5.3%  
Effective tax rate %50.327.8 180.5%   
Net profit margin %13.916.1 86.1%  
BALANCE SHEET DATA
Current assets Rs m9,5227,213 132.0%   
Current liabilities Rs m3,2962,104 156.7%   
Net working cap to sales %110.447.5 232.3%  
Current ratio x2.93.4 84.3%  
Inventory Days Days3754 67.2%  
Debtors Days Days2828 102.5%  
Net fixed assets Rs m466,865 0.7%   
Share capital Rs m123175 70.4%   
"Free" reserves Rs m7,21312,586 57.3%   
Net worth Rs m7,33612,761 57.5%   
Long term debt Rs m06 0.0%   
Total assets Rs m11,10515,041 73.8%  
Interest coverage x29.5173.2 17.0%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x0.50.7 71.0%   
Return on assets %7.611.6 65.0%  
Return on equity %10.713.6 78.6%  
Return on capital %22.219.0 117.2%  
Exports to sales %012.3 0.0%   
Imports to sales %00-   
Exports (fob) Rs mNA1,327 0.0%   
Imports (cif) Rs mNANA-   
Fx inflow Rs m611,889 3.2%   
Fx outflow Rs m3,6300-   
Net fx Rs m-3,5701,889 -189.0%   
CASH FLOW
From Operations Rs m1,6101,498 107.4%  
From Investments Rs m687201 341.6%  
From Financial Activity Rs m-2,677-1,694 158.0%  
Net Cashflow Rs m-38010 -3,685.4%  

Share Holding

Indian Promoters % 0.0 68.9 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 2.0 4.7 42.6%  
FIIs % 1.6 7.5 21.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.5 19.0 113.2%  
Shareholders   41,647 23,730 175.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   DR. DATSONS LABS  STRIDES PHARMA SCIENCE  J.B.CHEMICALS  JUBILANT LIFE SCIENCES  BIOCON   

Compare NOVARTIS With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slips Over 300 Points; Axis Bank & Tech Mahindra Top Losers(12:30 pm)

Share markets in India have extended early losses and are presently trading deep in the red. Barring consumer durables sector, all sectoral indices are trading in red with stocks in the telecom sector.

Related Views on News

NOVARTIS Announces Quarterly Results (1QFY20); Net Profit Down 92.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NOVARTIS has posted a net profit of Rs 8 m (down 92.1% YoY). Sales on the other hand came in at Rs 1 bn (down 20.8% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

FDC LTD. Announces Quarterly Results (1QFY20); Net Profit Up 2.4% (Quarterly Result Update)

Aug 6, 2019 | Updated on Aug 6, 2019

For the quarter ended June 2019, FDC LTD. has posted a net profit of Rs 523 m (up 2.4% YoY). Sales on the other hand came in at Rs 3 bn (up 17.9% YoY). Read on for a complete analysis of FDC LTD.'s quarterly results.

FDC LTD. Announces Quarterly Results (4QFY19); Net Profit Up 6.8% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, FDC LTD. has posted a net profit of Rs 337 m (up 6.8% YoY). Sales on the other hand came in at Rs 3 bn (down 0.6% YoY). Read on for a complete analysis of FDC LTD.'s quarterly results.

NOVARTIS Announces Quarterly Results (4QFY19); Net Profit Down 26.2% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, NOVARTIS has posted a net profit of Rs 195 m (down 26.2% YoY). Sales on the other hand came in at Rs 1 bn (down 11.9% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

FDC LTD. 2017-18 Annual Report Analysis (Annual Result Update)

Mar 28, 2019 | Updated on Mar 28, 2019

Here's an analysis of the annual report of FDC LTD. for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of FDC LTD.. Also includes updates on the valuation of FDC LTD..

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Don't Buy Lakshmi Vilas Bank...Buy this Private Sector Bank with 74% Upside(The 5 Minute Wrapup)

Sep 4, 2019

Lakshmi Vilas Bank is in a vicious cycle. The stock is already down 57% in 2019. Despite this, the retail investors increased their holding.

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Sep 17, 2019 01:53 PM

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NOVARTIS - PLETHICO PHARMA COMPARISON

COMPARE NOVARTIS WITH

MARKET STATS